Exicure Inc (FRA:2H0)
€ 1.48 0 (0%) Market Cap: 60.66 Mil Enterprise Value: 66.14 Mil PE Ratio: 0 PB Ratio: 41.48 GF Score: 31/100

Exicure Inc R&D Day - Virtual Transcript

Jan 07, 2021 / 02:00PM GMT
Release Date Price: €237 (-4.82%)
David A. Giljohann
Exicure, Inc. - CEO, Interim Principal Financial Officer, Corporate Secretary & Director

Hi, everybody, and welcome to Exicure's R&D Day. My name is David Giljohann, I'm the CEO of Exicure. And on behalf of the entire Exicure team and our guests today, thank you for joining us as we discuss how Exicure is building a leading platform in neurology and working to bring that platform into patients as fast as possible.

A couple of notes as we get started. We are a publicly traded company out of the ticker symbol XCUR. As such, we refer to -- you to our SEC guidance regarding forward-looking statements and nonsolicitation.

We have a dynamic group of speakers ready to go for today. In addition to myself, we have Matthias Schroff, our Chief Operating Officer; Doug Feltner, our Chief Medical Officer; Susan Perlman, a Clinical Professor of Neurology at UCLA; Jen Farmer from FARA; and our program managers for Neuro, Grant Corbett and Bart Anderson.

We're very pleased today to have Dr. Susan Perlman joining us. Susan Perlman is a Clinical Professor of Neurology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot